Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. The big US drugmaker pointed to another drop in ...

Pfizer’s PFE fourth-quarter results were strong as it beat estimates for both earnings and sales. Total revenues declined 3% on an operational basis due to a 40% decline in revenues from its COVID-19 ...

Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer delivered strong 3Q25 results, beating EPS and revenue estimates, and raised full-year EPS guidance while maintaining robust cost-saving targets. PFE's $10B acquisition of Metsera secures a ...

Pfizer last month completed an acquisition of biotech firm Metsera, deepening its portfolio of products in the fast-growing market for weight loss drugs - Copyright ...

For Q3 FY26, Pfizer reported a net profit of Rs 141.8 crore, up 11.1 per cent year-on-year (YoY), compared with Rs 127.6 crore in the corresponding period last year. Revenue climbed 19.9 per cent YoY ...